Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: A multi-country analysis

Authors: <u>Xiao Li</u> [1], Lander Willem [1], Caroline Klint Johannesen [2], Arantxa Urchueguía-Fornes [3,4], Toni Lehtonen [5], Richard Osei-Yeboah [6], Heini Salo [5], Alejandro Orrico-Sánchez [3,4,7], Javier Díez-Domingo [3,4,7], Mark Jit [8], for PROMISE investigators, Joke Bilcke [1], Harish Nair [6], Philippe Beutels [1]

Affiliation:

[1] Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), University of Antwerp, Belgium

[2] Department of Virology and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark

[3] Vaccine Research Department, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region (FISABIO), Valencia, Spain

[4] CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Valencia, Spain

[5] Finnish Institute for Health and Welfare, Helsinki, Finland

[6] Centre for Global Health, The University of Edinburgh, Edinburgh, United Kingdom

[7] Catholic University of Valencia, Valencia, Spain.

[8] Department of Infectious Disease Epidemiology & Dynamics, London School of Hygiene &

Tropical Medicine

Corresponding authors

Xiao Li

Address: Centre for Health Economics Research & Modelling Infectious Diseases,

Vaccine & Infectious Disease Institute, Campus Drie Eiken (D.R.212), Universiteitsplein 1

University of Antwerp, Belgium

Email: xiao.li@uantwerpen.be

Abstract

Background: We aimed to identify influential drivers of the cost-effectiveness of older adult respiratory syncytial virus (RSV) vaccination in Denmark, Finland, the Netherlands and Valencia-Spain.

Methods: A static multi-cohort model was parameterised using country- and age-specific hospitalisations using three approaches: (1) the International Classification of Diseases (ICD)-coded hospitalisations, (2) laboratory RSV-confirmed hospitalisations and (3) time-series modelling (TSM). Plausible hypothetical RSV vaccine characteristics were derived from two protein subunit vaccines for adults aged ≥60 years ("60y+"). Costs and quality-adjusted life-years (QALYs) were compared between four strategies: (a) "no intervention" and RSV vaccination in adults (b) 60y+; (c) 65y+; (d) 75y+, from both the healthcare payers' and societal perspectives. Value of information, probabilistic sensitivity and scenario analyses identified influential drivers.

Results: Besides vaccine price, the hospitalisation estimates were most influential: Using adjusted RSV-ICD-coded hospitalisations at a vaccine price of €150 per dose, no intervention was cost-effective up to willingness-to-pay (WTP) values of €150 000 per QALY gained in Denmark and the Netherlands, and up to €125 000 per QALY gained in Finland. Using the adjusted RSV-confirmed dataset, the findings were consistent in Denmark and comparable in Finland. In Spain-Valencia, the 75y+ strategy became cost-effective at WTP >€55 000. Using TSM-based estimates, the 75y+ strategy was cost-effective at WTP >€45 000, >€101 000, >€41 000 and >€114 000 in Denmark, Finland, the Netherlands and Spain-Valencia, respectively. The (in-hospital) case fatality ratio and the specification of its age dependency

were both influential. Duration of protection was found more influential than a variety of

plausible waning patterns over the duration of protection.

Conclusion: Data gaps and uncertainties on the RSV-related burden in older adults persist

and influence the cost-effectiveness of RSV vaccination. More refined age- and country-

specific data on the RSV attributable burden are crucial to aid decision making.

Key words: RSV, respiratory, vaccination, policy, ageing population, economic evaluation,

cost-utility analysis, cost-effectiveness analysis, uncertainty

1 Introduction

Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections (RTI) in

both young children and older adults. Among adults aged 60 years and above (60y+), a

meta-analysis estimated 5.2 million RSV cases, 470 000 hospitalisations and 33 000 in-

hospital deaths across high-income countries in 2019 [1]. With ageing populations in these

countries, this disease burden is expected to increase.

RSV is contagious and seasonal, and it typically peaks during the winter months in Europe, in

line with several other respiratory pathogens. RSV leads to a substantial burden, exerting

pressure on healthcare resources [2]. The RSV-related disease burden among European

older adults has not been well established, in terms of country- and age-specific

hospitalisation rates, which are essential ingredients for cost-effectiveness analyses.

Previous systematic reviews included multiple studies that reported hospitalisation rates,

but the majority of these studies were conducted outside of Europe [1, 3].

In 2023, two protein subunit RSV vaccines, Arexvy® (GSK) and Abrysvo® (Pfizer) were

approved for the prevention of RSV disease among adults aged 60y+ and marketed in

several high-income countries. In 2024, an mRNA-based vaccine mResvia® (Moderna) was

also approved [4]. All vaccines have demonstrated protective efficacy lasting for more than

one season, with waning immunity observed in the second season [5-8].

Recommendations on RSV immunisation in older adults were made by several National

Immunisation Technical Advisory Groups. In the US, the Advisory Committee on

Immunization Practices (ACIP) recommended a single-dose RSV vaccine for all adults 75y+

and adults aged 60-74 years who are at increased risk for severe RSV disease [9]. In the

United Kingdom (UK), the Joint Committee on Vaccination and Immunisation (JCVI) advised

a programme for older adults aged 75 years and above (75y+)[10]. Cost-effectiveness

analyses were conducted to inform these ACIP and JCVI recommendations.

The PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) Consortium

(https://imi-promise.eu/) aimed to produce new evidence on the burden of RSV disease in

Europe, before and after the emergence of severe acute respiratory syndrome coronavirus

2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). For instance, data on RSV

International Classification of Diseases (ICD)-coded and RSV-confirmed hospitalisations were

collected using national or regional registries in several countries. Moreover, time-series

modelling (TSM) was employed to estimate the RSV-attributable hospitalisations for these

countries.

We used the data on RSV hospitalisations generated by the PROMISE project to identify and

explore the influential parameters and assumptions driving the cost-effectiveness of RSV

vaccination strategies among older adults in four European countries: Denmark, Finland, the

Netherlands and Spain-Valencia. The choice of these countries was guided by the timely

availability of data of sufficient quality and detail within the PROMISE project (June 2024).

Methods

Cost-effectiveness model

We developed a static multi-cohort model (Figure 1) named Multi-Country Model

Application for RSV Cost-Effectiveness policy for Adults (MCMARCELA). The modelled

population consists of adults aged 60 to 99 years, who were tracked monthly over a five-

year time horizon, which aligns with the expected maximum protective duration of RSV

vaccine [11]. The model considered costs and quality-adjusted life-years (QALYs) lost for RSV

cases seen in primary care, admitted to hospitals, and symptomatic RSV cases requiring no

medical attendance (non-MA). It also assumed that RSV-related mortality occurs only in a

hospital setting. Premature RSV-related deaths were calculated from the model using

hospital-fatality ratios to estimate QALYs lost over the remaining life-expectancy at the age

of death. The model did not separately account for RSV cases requiring only an outpatient

visit in hospital or an emergency department visit without admission, because such type of

data was not available for most of the countries considered.

The model made comparisons between four strategies: "no intervention" and three age-

based single-dose universal RSV vaccination strategies among older adults. Each vaccination

strategy was modelled as if a single dose were offered to everyone in an age band at the

same time in October, prior to the start of the first RSV season considered over the 5-year

time horizon:

I.   60 years and above up to 99 years ('60y+' strategy) based on the approved age-

indication,

II.   65 years and above up to 99 years ('65y+' strategy) considering the universal

influenza vaccination programmes in many European countries,

III. 75 years and above up to 99 years ('75y+' strategy) based on the JCVI and ACIP

recommendation.

This analysis was conducted separately from a healthcare payers' (HCP) perspective

considering only direct medical costs and from a societal perspective, additionally including

costs associated with productivity losses of patients. Both costs and QALYs were discounted

at rates recommended by the country-specific pharmacoeconomic guidelines (see

Supplement Table 6) [12-15].

Model input parameters and assumptions

All parameters are listed in *Supplement Table 6*, and each input parameter is described in

detail *in Supplement section 1.1.*

In brief, for Denmark, Finland and the Netherlands, RSV-ICD-coded hospitalisations by age

and calendar month were estimated retrospectively using national registries. The RSV-

confirmed data were also obtained in Denmark and Finland using the same registries [16,

17]. In Valencia, a region of Spain, the RSV-confirmed hospitalisations were collected

retrospectively through their regional active hospital-based surveillance network

(descriptions in previous publications [18, 19]). The catchment area represented 21% of the

overall population in Valencia (approximately 1 million), or 0.2% of the population in Spain.

Patients meeting preliminary inclusion criteria and meeting the influenza-like-illness (ILI)

case definition [20] were included and systematically tested for RSV with a multiplex

polymerase chain reaction (PCR) test. RSV-confirmed data was adjusted to the RSV season

as active surveillance was not performed throughout the whole year [16, 21]. The brief

description of the data collection methods is in *Supplement section 1.1.1*, and the full details

are available elsewhere [16, 17].

Subsequently, a TSM analysis was conducted to attribute respiratory tract infection (RTI)

hospital admissions to RSV, using the number of positive virological isolates of respiratory

pathogens, including influenza A and B, SARS-CoV-2, and RSV, over time as covariates.

Under this approach influenza and RSV laboratory test frequency was regressed against RTI

incidence over time, to determine the proportion of RTI cases that were attributable to the

two viruses [22]. In Spain-Valencia, ILI was used instead of RTI in the TSM analysis and an

inference on missing weeks without active surveillance was performed in order to account

for the fact that data was not available throughout the whole year. The brief description of

the TSM analysis is in *Supplement section 1.1.1.3* and the full details are available elsewhere

[21].

To account for uncertainty on the choice of source data for the hospitalisation estimates,

we explored the cost-effectiveness of using

8   (1) the RSV-ICD-coded hospitalisations with an adjustment factor of 2.2 for

9   diagnostic under-ascertainment, except for Spain-Valencia due to insufficient sample size

10   [23].

11   (2) the RSV-confirmed hospitalisations with the adjustment factor of 2.2 (except for

12   the Netherlands due to data unavailability),

13   (3) the TSM estimated RSV-attributable hospitalisations.

The differences among the three hospitalisation datasets were illustrated in *Supplement*

Figures 1-4. We used the average data over three or four seasons (depending on data

availability) prior to the COVID-19 pandemic (2016/2017 to 2019/2020).

The RSV-related primary care episodes by age were estimated based on a meta-analysis of

US studies [24], which found for every RSV hospitalisation in adults aged 60y+, 8.5 RSV

primary care episodes occurred on average. We additionally used higher estimates of RSV-

related primary care episodes based on a UK modelling study in scenario analysis [25]. A

multi-country prospective study among European community-dwelling older adults

provided an estimate of 2.27 non-MA episodes per primary care episode [26, 27]. We used

7.13% (95% CI: 5.4-9.36) for the in-hospital case fatality ratio (hCFR) for all 60y+ based on a

meta-analysis [1]. The age-specific RSV-confirmed hCFRs in Finland were used in scenario

analysis.

In order to focus on identifying general drivers of cost-effectiveness of RSV vaccination

among older adults, and to avoid detractions due to minute interpretative differences in

differently defined product-specific clinical endpoints, we consider in this analysis the use of

a hypothetical RSV vaccine. We used plausible efficacy (mean and 95% CI) values against

non-MA episodes, primary care episodes, hospitalisations, and deaths by combining

information available at the time of the analysis for both Arexvy® and Abrysvo® (Table 1,

Supplement 2.1.5) [5, 6]. Based on waning assumptions made in published cost-

effectiveness analyses for older adults [28-32], we explored 13 waning scenarios

accommodating a range for the duration of protection from 18 months to 48 months

(*Supplement section 1.15*). The RSV vaccine price was assumed to be €150 per dose for all

countries in this study [33]. RSV vaccination coverage was based on country- and age-

specific influenza vaccination coverage (*Supplement Table 6*).

Country-specific costs were obtained for hospitalisations (including intensive care unit

admissions), primary care consultations, and vaccine administration (*Supplement section*

1.1.7). A cost of €4.06 per non-MA episode was used for all countries based on a European

multi-country prospective study [27]. From a societal perspective, the costs of productivity

losses were estimated using the human capital approach: the age- and country-specific daily

salaries were adjusted by employment rates and multiplied by the number of workdays lost.

We accounted for one and two lost workdays per non-MA and primary care episode,

respectively [34], and the country-specific length of hospital stay plus three days per

hospitalised case. Productivity losses due to RSV-associated premature deaths were not

included in order to avoid double counting [35]. All costs were inflated to their 2023 value using the country-specific consumer price index (CPI) of all sectors, and those reported in local currency were converted to euro (€) using the annual exchange rates of 2023 [36, 37].

QALY losses due to RSV deaths were estimated using remaining life expectancy at age of death and standard age-specific utility values by country [38, 39] (*Supplement section 1.1.8 and Table 6*). A prospective study in European older adults estimated an average QALY loss of 0.004 (95% CI: 0.001-0.010) per non-MA or primary care episode [34]. There was no utility value available for individuals aged 60y+ who were hospitalised with RSV. Hence, we assumed QALY losses of 0.01023 (95% CI: 0.0089-0.0170) based on another European multi-country prospective study among RSV-hospitalised infants' parents [40], this value was comparable to QALY losses in hospitalised influenza patients [41]. However, in scenario analysis, we also assumed alternative average QALY losses of 0.0185 (CI: 0.0053-0.0347) for non-hospitalised patients and 0.0193 (CI: 0.0095-0.0316) for hospitalised patients, based on a 2022 US ACIP meeting, subsequently published in Hutton et al [42].

Analytical approach

We conducted a full incremental analysis of costs and effects arising in all strategies to identify the cost-effective program for willingness-to-pay (WTP) values ranging from €0 to €150 000 per QALY gained [43, 44].

To evaluate the impact of uncertain input parameters on the estimated cost-effectiveness, the expected value of partial perfect information (EVPPI) was calculated over a range of WTP values through probabilistic sensitivity analysis. A probabilistic price threshold analysis was also performed for each country applying the method demonstrated by Pieters and colleagues [45].

To explore the impact of key assumptions and input parameters, we also conducted deterministic scenario analyses including 13 scenarios on vaccine characteristics (i.e., efficacy, duration of protection, waning curves), and 16 scenarios on input parameters such as burden of disease, QALY losses, RSV seasonality, price per dose, and the impact of the COVID-19 pandemic. An overview of scenarios analyses was summarised in *Supplement Tables 1 and 7 and section 1.4*. All analyses were conducted in R version 4.3.2.

Results

RSV health and economic burden without vaccination

Over a five-year time horizon, (1) using the adjusted RSV-ICD-coded dataset (*Supplement Table 10*), we estimated 30 910, 252 679, and 316 814 RSV cases (including non-MA, primary care episodes and hospitalisations), as well as 618, 4 780, and 8 905 discounted QALY losses among adults 60y+ in Denmark, Finland and the Netherlands, respectively. From the HCP and societal perspectives, the discounted costs were €3.8 and 4.3 million in Demark, €32.6 and €35.2 million in Finland, and €80.3 and €95.3 million in the Netherlands, respectively.

(2) Using the adjusted RSV-confirmed hospitalisation dataset, the estimated RSV cases were 84 852 in Denmark, 326 588 in Finland, and 74 083 in Spain-Valencia, as well as 1 677, 6 223, and 1 615 discounted QALY losses among adults 60y+ in Denmark, Finland and Spain-Valencia, respectively. From the HCP and societal perspectives, the discounted costs were €10.5 and 11.7 million in Demark, €42.2 and €45.6 million in Finland, and €11.0 and €11.3 million in Spain-Valencia, respectively.

(3) Using the TSM RSV-attributable estimates, we observed 24- and 9-fold higher RSV-

attributable cases (0.7 million) in Demark compared with the adjusted RSV-ICD-coded and

adjusted RSV-confirmed hospitalisations, respectively. Consequently, there were higher

QALY losses and direct medical and indirect medical costs. In the Netherlands, 4-fold higher

RSV-attributable cases (1.3 million) were estimated compared with using the adjusted RSV-

ICD-coded dataset. However, both in Finland and Spain-Valencia, the RSV-attributable cases

from the TSM were 11% (289 516) and 49% (37 895) lower than the adjusted RSV-confirmed

estimates, respectively. Consequently, large differences were observed in the discounted

QALY losses, and the direct and indirect costs attributable to RSV. Despite the large

differences in baseline disease burden while using different datasets, it was consistent that

the 75-84y age group had the highest number of hospitalisations (except the Netherlands

using adjusted RSV-ICD-coded dataset); consequently, the highest number of primary care

and non-MA episodes, and discounted medical costs. However, the highest discounted

QALY losses mainly occurred in the 65-74y age group (except Spain-Valencia). Most indirect

costs due to productivity losses occurred in the 60-64y age group, as it had the highest

active labour force participation.

RSV-burden averted with single-dose one-time vaccination over two years

protection

Irrespective of the hospitalisation data source, in every country the 60y+ strategy had the

greatest impact on disease burden in terms of cases, hospitalisations and deaths averted,

QALYs gained, and direct and indirect medical costs averted. However, this was also the

most expensive strategy with one-time vaccination costs of €195 million, €139 million, €482

million and €30 million in Denmark, Finland, the Netherlands, and Spain-Valencia,

respectively. Detailed RSV burden averted estimates are presented in *Supplement Tables 9,*

11 and 13 by strategy, country and methodological approach.

Cost-effectiveness

In general, more expansive vaccination strategies became cost-effective for the HCP with

increasing WTP values per QALY gained (Figures 2-4). A societal perspective increased the

potential cost savings per averted case, but the overall results remained comparable with

the HCP perspective (*Supplement Figures 8, 11 ,14 and 15*).

(1) Using the adjusted RSV-ICD-coded hospitalisations (Figure 2), 'no intervention' was cost-

effective up to a WTP value of €150 000 per QALY gained for the HCP in Denmark and the

Netherlands. In Finland, the 75y+ would be preferred at WTP values exceeding €124 000.

(2) Using the RSV-confirmed hospitalisations (Figure 3), the finding was consistent for

Denmark that 'no intervention' is cost-effective, whereas in Finland the 75y+ strategy

became preferred at lower WTP values (≥95 000) versus using adjusted RSV-ICD-coded

hospitalisations. In Spain-Valencia, the 75y+ and 65y+ strategies became cost-effective at

WTP values above €55 000 and €116 000, respectively.

(3) Using the TSM estimates (Figure 4), the 75y+ strategy was preferred if the WTP value

exceeded €45 000 in Denmark, €101 000 in Finland, €41 000 in the Netherlands, and €114

000 in Spain-Valencia. The 65y+ strategy became the preferred strategy at higher WTP

values of €65 000 in Denmark, and €70 000 in the Netherlands. In Finland and Spain-

Valencia, 65y+ strategy was not preferred up to a WTP value of €150 000.

In all four countries and using all hospitalisation data, the 60y+ strategy was not preferred

up to a WTP value of €150 000.

Influence of price

Variations in the vaccine price from €50 to €250 per dose changed the preferred strategy over a wide range of WTP levels from the HCP perspective. (1) Using the adjusted RSV-ICD-coded dataset (*Supplement Figure 17*), 'no intervention' was cost-effective in Denmark irrespective of WTP per QALY. However, at €50 per dose, in Finland the 75y+ strategy was cost-effective at a WTP value of €40 000, whereas in the Netherlands the 75y+ strategy could be cost-effective at a WTP value of €80 000. (2) Using the adjusted RSV-confirmed dataset (*Supplement Figure 18*), findings are consistent in Denmark and comparable in Finland versus adjusted ICD-coded hospitalisation. In Spain-Valencia, at €50 per dose, the 75y+ strategy would be cost-effective at a WTP value of €20 000 per QALY gained. (3) Using TSM estimates (Figure 5) and a price of €50 per dose, the 75y+ strategy would be cost-effective at a WTP of €20 000 per QALY gained in Denmark, €30 000 in Finland, €10 000 in the Netherlands, and €50 000 in Spain-Valencia. The 65y+ strategy would become cost-effective at higher WTP ranges per QALY gained: €30 000 in Denmark and the Netherlands, €80 000 in Finland, and €100 000 in Spain-Valencia. The 60y+ strategy might become cost-effective in Denmark and the Netherlands at WTP values of €100 000 and €120 000 per QALY gained, respectively. The price reductions led to sharp decreases in the WTP level at which strategies became cost-effective for Denmark and the Netherlands. This effect was less pronounced for Finland and Spain-Valencia. Overall, decision uncertainty was highest nearby the WTP values at which the cost-effective strategy switched.

Highly influential factors on the optimal strategy (other than price)

- Choice of datasets

The choice of optimal strategy at a given WTP level and price depended in all countries heavily on the choice of dataset to estimate the incidence of RSV hospitalisations (RSV-ICD-coded, RSV-confirmed and RSV-attributable).

- Hospital case fatality ratio (non-age specific and age-specific)

The hCFR was identified as another key driver. The EVPPI graphs demonstrated that the uncertainty around the non-age-specific hCFR caused the most decision uncertainty for all countries across all three datasets (Figure 6 and *Supplement Figures 10, 13 and 16)*.

Compared with assuming non-age-specific hCFR for adults 60y+, using relatively higher hCFRs among adults 75y+ made the 75y+ strategy preferred at lower WTP values, and lower hCFRs in the 60-64y and 65-74y age groups made the 65y+ strategy only preferable over the 75y+ strategy at much higher WTP values (*Supplement Figure 20*).

- RSV vaccine efficacy values against mortality

As illustrated by the EVPPI graphs, the uncertainty around first- and second-year RSV vaccine efficacy values against mortality were the top-ranking influential drivers (Figure 6, *Supplement Figures 10, 13 and 16*), because ca. 80% of the QALY gains came from the RSV-related deaths averted across all four countries.

- QALY losses due to non-medically attended cases

The large number of non-MA cases make the estimate of the number of non-MA episodes per primary care visit over its relatively wide uncertainty interval (2.27 [uniform distribution: 1.14-3.41]) influential for the costs per QALY gained estimates (Figure 6, *Supplement Figures 10, 13 and 16*).

- Adjustment factor for diagnostic under-ascertainment

The adjustment factor of 2.2 for diagnostic under-ascertainment of hospitalised cases was also influential when using the RSV-ICD-coded and RSV-confirmed datasets (*Supplement Figures 20*). Its parametric uncertainty was influential when using the adjusted RSV-ICD-coded and adjusted RSV-confirmed datasets (Figure 6 and *Supplement Figures 10 and 13*).

Other influential factors on the optimal strategy

The duration of protective efficacy showed more impact than the type of waning curve assumed (*Supplement Figure 19*). Scenarios considering a seasonal shift of RSV as observed during the COVID-19 pandemic, administering RSV vaccine prior to a "mild" season and applying lower vaccine efficacy in adults 80y+ all yielded negative impacts on the cost-effectiveness results compared to the reference analysis. Scenarios administering RSV vaccine prior to a "severe" season, using higher QALY losses associated with RSV illness and a higher ratio of hospital to primary care, led to more expansive cost-effective strategies (*Supplement Figure 15*). Nevertheless, RSV vaccine coverage increases in the 60-64y age group had limited impact (*Supplement Figure 15*), in the context of comparing multiple age-based RSV strategies using a single RSV vaccine at price of €150 per dose.

Discussion

We performed a full incremental analysis comparing no intervention and three vaccination strategies in adults aged 60, 65 and 75 years and above to each other using a hypothetical RSV vaccine which bridged phase 3 trial efficacy data available up to June 2024. Our analyses used three hospitalisation datasets in four countries to explore the influential drivers of the cost-effectiveness of RSV vaccination in European older adults. Although there are substantial differences observed among countries in term of cost-effectiveness, the

influential drivers are consistent across countries. We found that apart from the vaccine

price, the key driver of decision uncertainty regarding which strategy is cost-effective in all

countries is the choice of the RSV hospital admissions dataset to use. The top-ranking

uncertainty drivers are the non-age-specific hCFR, the vaccine efficacy values against

mortality and the adjustment for diagnostic under-ascertainment of hospitalised cases,

when using the adjusted RSV-ICD-coded and RSV-confirmed datasets. The uncertainty

around the ratio of non-MA cases per primary care visit was also particularly influential.

Since RSV clinical symptoms are indistinguishable from those of many other respiratory

virus infections and laboratory testing for RSV is relatively rare in older European adults,

RSV-ICD-coded hospitalisation rates can substantially underestimate the disease burden,

especially in countries without routine RSV testing [26, 46]. We, therefore, investigated the

impact of using RSV-ICD-coded (except Spain-Valencia), RSV-confirmed (except the

Netherlands), or TSM model-based RSV-attributable hospitalisations to inform RSV

hospitalisation rates. We showed this impact to be very high. For instance, after applying an

adjustment factor of 2.2 to the RSV-ICD-coded hospitalisations and RSV-confirmed, no

intervention was cost-effective up to the WTP value of €150 000 per QALY gained in

Denmark and the Netherlands, and up to €124 000 per QALY gained in Finland. No

intervention was cost-effective up to a WTP value of €55 000, in Spain-Valencia when using

adjusted RSV-confirmed hospitalisations. However, model-based analyses of TSM data

yielded increased age-specific RSV attributability, and when using the resulting

hospitalisation rates, the 75y+ strategy was shown to be cost-effective at much lower WTP

values per QALY gained in Denmark and the Netherlands.

The TSM-based approach used in this analysis is a method commonly used to estimate the

burden of many other diseases such as influenza [47]. In our analysis, we used laboratory

test data series on four pathogens (influenza A, influenza B, SARS-CoV-2 and RSV) that cause

RTIs (in Spain-Valencia, ILI was used as a proxy for RTI). Although these are four highly

important pathogens for RTIs, this is not an exhaustive inclusion of potential causative

pathogens and, therefore, the attributable fractions estimated for each or some of these

pathogens to RTI hospitalisation may be overestimations, although this was partially

adjusted for by including a constant term. On the other hand, RSV-ICD-coded hospital

admission data are likely to substantially underestimate RSV-related hospital admissions [46,

48]. RSV diagnostic tests were also not systematically performed except in Spain-Valencia.

When adjusting RSV-ICD-coded and RSV-confirmed datasets with the diagnostic under-

ascertainment factor of 2.2, the findings were substantially different than those using TSM

estimates in Denmark. The large differences were also observed in the Netherlands when

comparing the adjusted RSV-ICD-coded hospitalisation with the TSM estimates. However,

the results of using three datasets were comparable in Finland. In Spain-Valencia, the

adjusted-RSV-confirmed dataset showed more favourable results for RSV vaccination. This

could be explained by the fact that testing was already systematic in all included in patients

in Spain-Valencia. However, the use of ILI as inclusion criteria (in Spain-Valencia) is known to

underestimate the real RSV burden in the surveillance networks compared to other case

definitions an under-ascertainment that has not been corrected for here [26, 49, 50]. Hence,

the adjustment factor and its uncertainty need to be interpreted with caution, taking into

account country-specific coding and testing practices.

Moreover, the hCFR and the specification of its age dependency were influential

(*Supplement Figures 10, 13, 15 and 20*). Despite the efforts to link the RSV-confirmed deaths

with hospital and mortality registries of multiple countries, we were only able to use the

age-specific hCFR for Finland, which had a sufficient sample size and was compliant with the

applicable data privacy law. Importantly, we demonstrated that acknowledging the age-

dependent nature of the hCFR is important when selecting optimal age-based RSV

vaccination strategies in older adults.

Our price threshold analysis showed that different "vaccine price per dose" thresholds exist

for different "WTP per QALY" levels, implying different optimal choices of strategies. When

considering vaccination strategies among 60y+, 65y+ and 75y+, the strategy protecting the

oldest (75y+) age group is first selected from the HCP perspective. With increasing WTP

values or decreases in price, the 65y+ and 60y+ strategies might become the optimal

strategy. Embedded in our calculations is the budget impact. Clearly, the smaller older-age

cohorts have a budgetary advantage over larger younger-age ones. In many countries,

budget-impact considerations may determine the choice of preferred strategy as much as

cost-effectiveness considerations do. For instance, Hodgson and colleagues assumed one

year protection and estimated the threshold price at which the 75y+ strategy can be cost-

effective at a much higher price (£20.71) than the price (£3.63) at which it would be

considered affordable, given a UK-set budget constraint for an individual programme of £20

million annually during the first three years of implementation [51].

By exploring many different waning efficacy profiles, we found that duration of protection is

more influential than the type of waning curve to achieve a cost-effective result. However,

this is for a single vaccine analysis and is likely to become more nuanced in head-to-head

comparisons of different vaccine brands, especially so when vaccines are marketed to

compete more on marginal differences in age-specific protective efficacy over time than on

more influential differences in price-setting. Given the trial-based information available, with different case definitions of the clinical endpoints of the licensed vaccines, such a head-to-head comparison is beyond the scope of this paper.

We assumed the RSV vaccines would be administered prior to the expected RSV season in Europe in October (with instant protection) in order to maximise the effectiveness. However, depending on the country, influenza, pneumococcal and COVID-19 vaccines are also typically administered in the last quarter of the calendar year in the same target populations, which can lead to implementation challenges for RSV vaccines due to crowded schedules. Given that RSV vaccines protect longer than one season, a year-round programme might be considered, possibly together with the pneumococcal or herpes zoster vaccine among older adults. However, given the clear seasonal pattern of RSV in Europe, a year-round programme would be less effective than a seasonal programme due to waning protection. Moreover, the coverage of pneumococcal vaccines is generally lower than the coverage of influenza vaccines among adults 65 years and above in Europe. Joint advice for RSV, influenza and COVID-19 vaccine before the winter might simplify the communication and, hence, achieve higher coverage.

This is the first analysis that assessed the cost-effectiveness of three age-based RSV vaccination strategies among older adults in more than two countries and identified the key evidence gaps that were most influential to cost-effectiveness. Previous analyses on a single country or two countries did not explore the sensitivity to different data sources, the influence of a shift in seasonality and the severity of a season [30, 31, 41, 51, 52]. Our results are comparable with two cost-effectiveness analyses published in 2023, which applied vaccine protection over two RSV seasons. Moghadas and colleagues evaluated both

marketed RSV vaccines in the US among adults aged 60y+ from a societal perspective. They

concluded that both vaccines can be cost-effective at a price of $235 (~€219) and $245

(~€228) per dose given a WTP value of $95 000 (~€88 000) per QALY gained, with sensitivity

analyses on WTP values of $80 000 (~€75 000) and $120 000 (~110 000) per QALY gained

[30]. Using the time-series estimates, we find that from the HCP's perspective and at an RSV

vaccine price of €200 per dose, the 65y+ strategy would be cost-effective only at high WTP

values of €90 000 and €100 000 per QALY gained in Denmark and the Netherlands,

respectively. We used age-specific hospitalisation rates, which led to much higher estimates

for the 85y+ age group (~366 per 100 000 in the Netherlands and 533 per 100 000 in

Denmark) in comparison to Moghadas et al (214 per 100 000 for any adult aged 60y+, with a

54.8% proportion in 85y+) [30]. However, Moghadas et al included both market and non-

market productivity losses due to RSV premature deaths based on US guidelines. Using a

cost-utility framework as prescribed by the pharmacoeconomic guidelines for the countries

in our study, we did not include such monetised productivity costs. Wang and colleagues

conducted a cost-effectiveness analysis in Hong Kong and used adjusted hospitalisation

rates ranging from 23.0 to 221.4 per 100 000 in the 60-64y and 75y+ age groups,

respectively [31]. By adjusting ICD-coded hospitalisations, our analysis estimated a lower

rate in Denmark (4.2 and 17.8 per 100 000), the Netherlands (0.4 and 2.2 per 100 000) and

Spain (2.6 and 13.1 per 100 000), but a higher rate in Finland (37.1 and 168.0 per 100 000).

The Hong Kong analysis also generally highlighted the price and disease burden as

influential drivers for the cost-effectiveness analysis, as did previous analyses, which

assumed protection over one RSV season [41, 51, 52].

Unlike in the UK, where the WTP thresholds of £20 000 (~€24 000) and £30 000 (~€35 000)

per QALY gained from the National Health Service (NHS) perspective are clearly indicated,

the four European countries in our analysis do not have an explicit WTP reference value [53].

In Denmark, a WTP value of DKK 88000 (~€12 000) per QALY gained was estimated via a

population survey in 2001, which might need updating [54]. In Finland, infant varicella,

pneumococcal and rotavirus vaccination programmes were considered to be cost-effective

at WTP values ranging from €15 000 to €25 000 per QALY gained from HCP perspective [55].

In the Netherlands, the reference values of €20 000, €50 000 and €80 000 per QALY gained

depended on the disease severity and perspective [56]. In Spain, a threshold of €30 000

from the NHS perspective is commonly cited [57]. Instead of using one or multiple arbitrary

threshold values, our analysis presented findings over a range of WTP values (€0-150 000

per QALY gained) to assess the influence of the WTP value on the optimal choice.

Our study has some additional strengths. It used the most recent country-specific data to

populate the model according to country-specific pharmacoeconomic guidelines.

Considerable differences in the RSV health and economic burden exist between countries,

and policy makers should reflect on these when making decisions. Most strikingly, RSV

seasonality changed during the COVID-19 pandemic in many countries. Therefore, we

simulated an off-season hospital admission peak (four months earlier) observed during the

pandemic and found the results would be less favourable because administering RSV

vaccine in October would miss either a portion or the entirety of the seasonal peak.

Furthermore, we also investigated RSV vaccine introduction in a country with a biannual

seasonal pattern and found that is considerably more beneficial to introduce the vaccine

first prior to a predicted "severe" season than a "mild" season. Furthermore, we explored

multiple vaccine efficacy waning scenarios in combination with duration of protection based

on the latest clinical data and demonstrated that the duration of protection have more

impact than the type of waning curve assumed. Finally, extensive sensitivity analyses were

performed using a wide range of WTP values to investigate the sensitivity of the optimal

choice of strategy to the adopted WTP level.

An important limitation of our analysis is that we investigated age-based and not risk group-

based strategies. We investigated one-time RSV vaccination, but did not attempt to model

scenarios with repetitive vaccination of cohorts over time. Future refined information on

vaccine effectiveness and durability may allow the evaluation of such strategies realistically

in future. Moreover, hCFR was used to estimate RSV-related deaths in the inpatient setting.

However, deaths that occurred in community setting (i.e., nursing home) were not captured

due to data availability, hence, it might underestimate cost-effectiveness of the RSV vaccine.

There are a few other limitations. Due to data limitations, the hospitalisation rate of a wide

age group (18-64 years) was applied to a small subgroup (60-64 years) in all four countries

when using TSM estimates. However, the impact on the overall insights from this analysis

was negligible. We were unable to explicitly evaluate the impact of potentially

disproportionately prevented re-admissions, long-term consequences due to RSV

hospitalisation (e.g., transfer to a nursing home instead of home after discharge), RSV

vaccine's potential prevention of exacerbations of chronic respiratory disease and cardiac

events [58], and productivity losses of caregivers under the societal perspective, mainly

because the occurrence of, and effectiveness against, these endpoints were unavailable.

Conclusion

Large data gaps and uncertainties around the RSV burden among older adults persist in

many European countries, contributing to substantial uncertainties regarding the cost-

effectiveness of intervention programs. Given that these countries need to make urgent

decisions about RSV vaccination, more refined age-, risk group-, and country-specific RSV

burden data are crucial. Evidence-based vaccine introduction decisions will require greater

investment in enhanced RSV surveillance and better data linkage systems to enable

accurate assessments of the age- and country-specific RSV burden, especially in tertiary and

primary care settings, such as those established in Finland. Without this, costly and

potentially suboptimal decisions risk being made, leading to substantial opportunity costs

due to the large target populations to be vaccinated.

Figures and Tables

Table 1: Phase 3 vaccine efficacy data of Arexvy® and Abrysvo® and the efficacy values of an RSV hypothetical vaccine.

Arexvy® (GSK)			Abrysvo® (Pfizer)		
Endpoints	Season 1 (full season)	Season 2 (full season)	Endpoints	Season 1 (full season)	Season 2 (full season)
			ARI ≥1 symptom	62.1% (95% CI:37.1-77.9)	Not shared in public domain yet
ARI ≥2 symptoms or sign	71.7% (95% CI: 56.2-82.3)	40.6% (95% CI: 19.0–57.0)			
LRTD ≥2 symptoms including ≥1 sign or ≥3 symptoms	82.6% (96.95% CI: 57.9-94.1)	56.1% (95% CI: 28.2-74.4)	LRTD ≥2 symptoms or signs	66.7% (96.66% CI: 28.8-85.8)	55.7% (95% CI: 34.7-70.4)
			LRTD ≥3 symptoms or signs	85.7% (96.66% CI: 32-98.7)	77.8% (95% CI: 51.4-91.1)
Severe LRTD (≥2 signs or defined as severe by investigator)	94.1% (95% CI: 62.4-99.9)	64.2% (95% CI: 61.6-93.4%)			
RSV hypothetical vaccine					
Vaccine efficacy against	Season 1 (full season)		Season 2 (full season)		
Non-MA	65% (35–85%)		35% (15-60%)		
Primary care	65% (35–85%)		35% (15-60%)		
Hospitalisation	80% (35-95%)		55% (25-80%)		
Death	90% (60-100%)		60% (55-95%)		

Abbreviations: ARI: acute respiratory infection, LRTD: lower respiratory tract disease

Figure 1: Model structure.

Footnote: primary care visits were estimated from hospitalisations, and non-medical attendance were estimated from primary care visits.

Figure 2: Using adjusted RSV-ICD-coded disease burden: preferred strategy based on cost-effectiveness analysis from the

healthcare payers' perspective.

Note: The RSV vaccine price per dose assumed is €150.

Abbreviations: QALY: quality-adjusted life-year, EUR: euro

Figure 3: Using adjusted RSV-confirmed disease burden: preferred strategy based on cost-effectiveness analysis from the

healthcare payers' perspective.

Note: The RSV vaccine price per dose assumed is €150. Spain: Valencia region in this analysis

Abbreviations: QALY: quality-adjusted life-year, EUR: euro

1   *Figure 4: Using time-series-modelling RSV estimates: preferred strategy based on cost-effectiveness analysis from the*

2   *healthcare payers' perspective.*

4   *Note: The RSV vaccine price per dose assumed is €150. Spain: Valencia region in this analysis*

5   *Abbreviations: QALY: quality-adjusted life-year, EUR: euro*

1   *Figure 5: Using TSM estimates: Price threshold analysis showing the cost-effective strategy at different WTP thresholds*

2   *from HCP's perspective.*

3   *Abbreviation: TSM: time-series modelling; HCP: healthcare payers' perspective; QALY: quality-adjusted life-year*

1   *Figure 6: Expected value of partial perfect information for Finland, using three different hospitalisation datasets.*

1   *Abbreviations: RSV: respiratory syncytial virus; TSM: time-series modelling, QALY: quality-adjusted life-year*

3   List of abbreviation

ACIP: Advisory Committee on Immunization Practices

CI: confidence interval

COVID-19: coronavirus disease 2019

CPI: consumer price index

EVPPI: expected value of partial perfect information

hCFR: in-hospital case fatality ratio

HCP: healthcare payer

ICD: International Classification of Diseases

ILI: influenza-like-illness

JCVI: Joint Committee on Vaccination and Immunisation

MA: medical attendance

MCMARCELA: Multi-Country Model Application for RSV Cost-Effectiveness policy for Adults

PCR: polymerase chain reaction

PROMISE: Preparing for RSV Immunisation and Surveillance in Europe

QALY: quality-adjusted life-years

RSV: respiratory syncytial virus

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

TSM: time-series modelling

UK: United Kingdom

US: United States

WTP: willingness-to-pay

Y: year

Declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Availability of data and materials

Almost all the data analysed and generated during this study are included in this published article and its supplementary files. Formal requests for additional data can be made to the corresponding author (XL) or the senior author (PB).

Funding

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement number 101034339. The JU receives support from the European Union's Horizon 2020 research and innovation program and European Federation of Pharmaceutical Industries Associations. MJ received funding from the NIHR Health Protection Research Units in Modelling and Health Economics (NIHR200908) and Immunisation (NIHR200929).

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Competing interests

Outside the submitted work, PB declares funding received by his institute from Merck for research on varicella-zoster and Pfizer for research on pneumococcus vaccine, XL declares

funding received by her institute from Icosavax, but they have not received any personal

fees or other personal benefits. CKJ reports a research grant from Nordsjællands Hospital,

travel grants from the University of Copenhagen, William Demants Fond in Denmark, and

the European Society of Clinical Virology and expert consultation fees from Sanofi, outside

of the submitted work. Outside the submitted work, HN declares consulting fees received

from WHO, Pfizer, Bill and Medlinda Bill and Melinda Gates Foundation and Sanofi,

honoraria for lectures/presentations from Astra Zeneca, GSK and Pfizer paid to his

institution, travel grants from Pfizer and Sanofi, and participation on a Data Safety

Monitoring Board or Advisory Board of GSK, Sanofi, Merck, Icosavax, Pfizer (paid to his

institution), as well as WHO and ResViNET (unpaid). AUF declares grants/contracts from

Moderna and VAC4EU paid to her institution, outside submitted work. AOS and JDD

declares grants/contracts from Moderna, MSD and GSK paid to their institution, outside

submitted work. AOS also declares consultancy fees from GSK and Moderna,

outside submitted work. JDD declares consultancy fees and honoraria from GSK, Pfizer and

MSD, and travel grants from Sanofi and GSK, outside the submitted work. HS declares

attending Adult Immunization Board meetings twice a year, the meetings (and travel) are

funded by an unrestricted grant from Vaccines Europe, outside submitted work. LW

declares grants received from Research Foundation Flanders (FWO), Antwerp University

Research Council and Horizon Europe 2.1 – Health paid to his institute, outside the

submitted work. MJ declares research grants from NIHR, RCUK, BMGF, WHO, Gavi,

Wellcome Trust, European Commission, InnoHK, TFGH, CDC, Gates Foundation paid to his

institution, outside the submitted work.

Other authors declared no competing interests.

Authors' contributions

PB and HN initiated and supervised the study. XL, LW, JB and PB conceptualised the study. XL analysed input data, performed literature searches and auxiliary data collection. XL, LW and JB wrote the cost-effectiveness model codes. XL performed the cost-effectiveness analyses. CKJ, AUF, and LT conducted national/regional database analyses, and collected and validated data in Denmark, Spain-Valencia, and Finland, respectively. CKJ, ROY, and TL led and estimated the time-series model-based hospitalisations. HS, AOS and JDD provided implementation, resource use and cost data for Finland and Spain. HN, MJ, JB and PB advised on model parameters, intervention characteristics and scenario analyses. XL, LW, JB and PB wrote the initial manuscript draft. All authors critically reviewed the manuscript and provided final approval of the manuscript.

Acknowledgements

PROMISE investigators: Harish Nair and Harry Campbell (University of Edinburgh, Edinburgh, UK); Louis Bont (University Medical Centre, Utrecht, the Netherlands); Philippe Beutels (University of Antwerp, Antwerp, Belgium), Peter Openshaw (Imperial College, London, UK), Andrew Pollard (University of Oxford, Oxford, UK), Hanna Nohynek (Finnish Institute for Health and Welfare, Helsinki, Finland), John Paget (Netherlands Institute for Health Services Research, Utrecht, Netherlands), Eva Molero (Teamit Research S.L., Barcelona, Spain), Javier Díez-Domingo (Vaccine Research Department, FISABIO-Public Health and CIBERESP, ISCIII, Valencia, Spain), Rolf Kramer (Sanofi Pasteur, Lyon, France), Jim Janimak (GlaxoSmithKline, Wavre, Belgium), Veena Kumar (Novavax, Gaithersburg, Maryland, United States), Elizabeth Begier (Pfizer Limited, New York City, New York, United States), Jenny Hendri (Janssen, Beerse, Belgium).

1   The authors would like to thank You Li, Valerie Sankatsing and Matthieu Beuvelet for their

2   critical review of our study report and valuable comments.

Reference

1. Savic M, Penders Y, Shi T, Branche A, Pircon JY: **Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis**. *Influenza Other Respir Viruses* 2023, **17**(1):e13031.

2. Li Y, Wang X, Broberg EK, Campbell H, Nair H, European RSVSN: **Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019**. *Euro Surveill* 2022, **27**(16).

3. Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H: **Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis**. *J Infect Dis* 2022, **226**(Suppl 1):S17-s21.

4. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J, Duncan CJA, Ujiie M, Ramet M *et al*: **Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older Adults**. *N Engl J Med* 2023, **389**(24):2233-2244.

5. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K *et al*: **Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults**. *N Engl J Med* 2023, **388**(16):1465-1477.

6. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N *et al*: **Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults**. *N Engl J Med* 2023, **388**(7):595-608.

7. Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN *et al*: **Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons**. *Clin Infect Dis* 2024.

8. **Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults** [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two]

9. **ACIP Recommendations** [https://www.cdc.gov/vaccines/acip/recommendations.html]

10. **Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June 2023** [https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023]

11. Van Effelterre T, Hens N, White LJ, Gravenstein S, Bastian AR, Buyukkaramikli N, Cheng CY, Hartnett J, Krishnarajah G, Weber K *et al*: **Modeling Respiratory Syncytial Virus Adult Vaccination in the United States With a Dynamic Transmission Model**. *Clin Infect Dis* 2023, **77**(3):480-489.

12. Alban A, Gyldmark M, Pedersen AV, Sogaard J: **The Danish approach to standards for economic evaluation methodologies**. *Pharmacoeconomics* 1997, **12**(6):627-636.

13. **Preparing a Health Economic Evaluation to Be Attached to the Application for Reimbursement Status and Wholesale Price for a Medicinal Product. Application Instructions (December 2019)** [https://tools.ispor.org/PEguidelines/source/2011Pricing_Board_Guidance_HEevaluation_english.pdf]

14. Hakkaart-van Roijen L, Peeters S, Kanters T: **Kostenhandleiding voor economische evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen (Herziene versie 2024)**. In. Edited by Institute for Medical Technology Assessment Erasmus Universiteit Rotterdam. Online; 2024.

15. Lopez Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J: **[A proposed guideline for economic evaluation of health technologies]**. *Gac Sanit* 2010, **24**(2):154-170.

16. **PROMISE deliverable: D1.6 RSV healthcare burden in young children and the elderly in 6 European countries before and since the emergence of the COVID-19 pandemic** [www.ed.ac.uk/sites/default/files/atoms/files/pr0a0d_1.pdf]

17. Urchueguía-Fornes A, Osei-Yeboah R, Jollivet O, Johannesen CK, Lehtonen T, van Boven M, Gideonse D, Cohen RA, Orrico-Sánchez A, Kramer R *et al*: **RSV healthcare burden in adults before and since the emergence of the COVID-19 pandemic in 6 European countries**. *medRxic (preprint)* 2024.

18. Mira-Iglesias A, Demont C, Lopez-Labrador FX, Mengual-Chulia B, Garcia-Rubio J, Carballido-Fernandez M, Tortajada-Girbes M, Mollar-Maseres J, Schwarz-Chavarri G, Puig-Barbera J *et al*: **Role of age and birth month in infants hospitalized with RSV-confirmed disease in the Valencia Region, Spain**. *Influenza Other Respir Viruses* 2022, **16**(2):328-339.

19. Mira-Iglesias A, Lopez-Labrador FX, Guglieri-Lopez B, Tortajada-Girbes M, Baselga-Moreno V, Cano L, Mollar-Maseres J, Carballido-Fernandez M, Schwarz-Chavarri G, Diez-Domingo J *et al*: **Influenza vaccine effectiveness in preventing hospitalisation of individuals 60 years of age and over with laboratory-confirmed influenza, Valencia Region, Spain, influenza season 2016/17**. *Euro Surveill* 2018, **23**(8).

20. The European Commission: **DECISIONS COMMISSION IMPLEMENTING DECISION (EU) 2018/945 of 22 June 2018** *Official Journal of the European Union* 2018.

21. **PROMISE deliverable: D1.7 Report on impact of COVID-19 and COVID-19 NPIs on RSV healthcare burden** [www.ed.ac.uk/sites/default/files/atoms/files/promise_d1.7_report_on_impact_of_covid-19_and_covid-19_npis_on_rsv_healthcare_burden_v1.0.pdf]

22. Johannesen CK, van Wijhe M, Tong S, Fernandez LV, Heikkinen T, van Boven M, Wang X, Boas H, Li Y, Campbell H *et al*: **Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis**. *J Infect Dis* 2022.

23. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, Nair H: **Adjusting for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older Adults in High-Income Countries: a Systematic Review and Modelling Study**. *Infect Dis Ther* 2023, **12**(4):1137-1149.

24. McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Simoes EAF, Swerdlow DL: **Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis**. *J Infect Dis* 2020.

25. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, Logie J, Matias G, Taylor S: **Modelling estimates of the burden of Respiratory Syncytial virus infection in adults and the elderly in the United Kingdom**. *BMC Infect Dis* 2015, **15**:443.

26. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, Allen J, Falsey A, Pircon JY, Gruselle O *et al*: **Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study**. *Eur Respir J* 2020.

27. Mao Z, Li X, Korsten K, Bont L, Butler C, Wildenbeest J, Coenen S, Hens N, Bilcke J, Beutels P: **Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults**. *J Infect Dis* 2022, **226**(Suppl 1):S87-s94.

28. Hutton DW: **Economic Analysis of RSV Vaccination in Older Adults**. In: *ACIP Presentation Slides: June 21-23, 2023 Meeting: 2023*; 2023.

29. Ortega-Sanchez IR: **Economics of Vaccinating U.S. Adults ≥60 years-old against Respiratory Syncytial Virus**. In: *ACIP Presentation Slides: June 21-23, 2023 Meeting: 2023*; 2023.

30. Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP: **Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States**. *Clin Infect Dis* 2023.

31. Wang Y, Fekadu G, You JHS: **Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong**. *Vaccines (Basel)* 2023, **11**(10).

32. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P: **Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?** *Vaccine* 2012, **30**(17):2795-2800.

33. GSK: **Arexvy product leaflet (ESWI conference)**. In. The European Scientific Working Group on Influenza (ESWI) 2023.

34. Mao Z, Li X, Dacosta A, Billard M, Wildenbeest J, Korsten K, Bont L, Martinón-Torres F, Heikkinen T, Cunningham S *et al*: **Costs and health-related quality of life of respiratory syncytial virus (RSV) infection among infants and their caregivers in Europe (under review)**. *Vaccine* 2022.

35. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: **Methods for the Economic Evaluation of Health Care Programmes**, Fourth edn. Oxford: Oxford University Press; 2015.

36. **HICP - annual data (average index and rate of change)** [https://ec.europa.eu/eurostat/databrowser/view/prc_hicp_aind/default/table?lang=en&category=prc.prc_hicp]

37. **ECU/EUR exchange rates versus national currencies** [https://ec.europa.eu/eurostat/databrowser/view/tec00033/default/table?lang=en]

38. Janssen MF, Szende A, Cabases J, Ramos-Goni JM, Vilagut G, Konig HH: **Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries**. *Eur J Health Econ* 2019, **20**(2):205-216.

39. Koskinen S, Lundqvist A, Ristiluoma N: **Health, functional capacity and welfare in Finland in 2011**. In. Helsinki, Finland: National Institute for Health and Welfare (THL); 2012: 290.

40. Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, Martinon-Torres F, Heikkinen T, Cunningham S, Snape MD *et al*: **Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: A multi-country prospective cohort study in Europe**. *Vaccine* 2023.

41. Zeevat F, Luttjeboer J, Paulissen JHJ, van der Schans J, Beutels P, Boersma C, Postma MJ, Investigators R: **Exploratory Analysis of the Economically Justifiable Price of a Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United Kingdom**. *J Infect Dis* 2022, **226**(Supplement_1):S102-S109.

42. Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, Havers FP, Prill MM, Whitaker M, Roper LE *et al*: **Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus**. *Vaccine* 2024, **42**(24):126294.

43. Bilcke J, Beutels P: **Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice**. *Med Decis Making* 2022, **42**(4):421-435.

44. Briggs AC, K. Sculpher, M: **Decision Modelling for Health Economic Evaluation**. Oxford: Oxford University Press; 2006.

45. Pieters Z, Strong M, Pitzer VE, Beutels P, Bilcke J: **A Computationally Efficient Method for Probabilistic Parameter Threshold Analysis for Health Economic Evaluations**. *Med Decis Making* 2020, **40**(5):669-679.

46. Egeskov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK: **Underreporting and misclassification of RSV-coded hospitalization among adults in Denmark between 2015/16 to 2017/18**. *J Infect Dis* 2023.

47. Johannesen CK, Gideonse D, Osei-Yeboah R, Lehtonen T, Jollivet O, Cohen RA, Urchueguía-Fornes A, Herrero-Silvestre M, López-Lacort M, Kramer R *et al*: **Underreporting of respiratory syncytial virus-associated hospital admissions in five European countries revealed through time series analysis**. *Under preparation (pre-print available upon request)* 2024.

48. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S: **Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance**. *Influenza Other Respir Viruses* 2020, **14**(6):630-637.

49. Saez-Lopez E, Pechirra P, Costa I, Cristovao P, Conde P, Machado A, Rodrigues AP, Guiomar R: **Performance of surveillance case definitions for respiratory syncytial**

virus infections through the sentinel influenza surveillance system, Portugal, 2010 to 2018. *Euro Surveill* 2019, **24**(45).

50. Hirve S, Crawford N, Palekar R, Zhang W, Group WRs: **Clinical characteristics, predictors, and performance of case definition-Interim results from the WHO global respiratory syncytial virus surveillance pilot**. *Influenza Other Respir Viruses* 2020, **14**(6):647-657.

51. Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE: **Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis**. *BMC Med* 2020, **18**(1):348.

52. Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B: **Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States**. *Vaccine* 2022, **40**(3):483-493.

53. Appleby J, Devlin N, Parkin D: **NICE's cost effectiveness threshold**. *BMJ* 2007, **335**(7616):358-359.

54. Gyrd-Hansen D: **Willingness to pay for a QALY**. *Health Econ* 2003, **12**(12):1049-1060.

55. Heini S: **Economic evaluations in adopting new vaccines in the Finnish national vaccination programme**. University of Helsinki; 2017.

56. Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman AM, Akehurst RL: **Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands**. *Value Health* 2022, **25**(1):91-103.

57. Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P: **Estimating a cost-effectiveness threshold for the Spanish NHS**. *Health Econ* 2018, **27**(4):746-761.

58. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, Austin E, Yousey-Hindes K, Openo KP, Ryan P *et al*: **Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection**. *JAMA Intern Med* 2024, **184**(6):602-611.